on-interventional Study on the Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Recruiting

• Conditions: E78.0; Pure hypercholesterolaemia

• Registration Number: DRKS00024153
• Lead Sponsor: Daiichi Sankyo Europe

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 4250

Inclusion Criteria

Written informed consent to participate
At least 18 years of age
Patients suffering from documented hypercholesterolemia or mixed dyslipidemia treated or intended to be treated with bempedoic acid/ FDC at the discretion of the physician are appropriate for participation in the observation.
No contraindications exist according to the SmPC of bempedoic acid/ FDC
No concurrent participation in an interventional study (Simultaneous participation in other non-interventional studies is possible)
Life expectancy > 1 year

Exclusion Criteria

As this is a non-interventional study, no explicit exclusion criteria are defined.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary objective is to describe in the real-world setting patient characteristics and outcomes of patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia using bempedoic acid/FDC in managing plasma levels of LDL-C.